Roel M. Huisman7
Sangeeta Pahuja5
AnthonyE. G Raine5
Harshwardhan V Tanwar5
Manjula Jain5
5Philip R. Spandorfer
5Gisele Lins Antunes
5Seema R Bhatt
2Susanne Seidinger
2Brian D. Bradbury

Filter Results:

  • Full text PDF available (10)

Publication Year

2000
2018
  • This year (5)
  • Last 5 years (8)
  • Last 10 years (21)

Publication Type

Co-author

Journals and Conferences

Learn More
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
BACKGROUND Optimal treatment for secondary hyperparathyroidism (SHPT) has not been defined. The IMPACT SHPT (ClinicalTrials.gov identifier: NCT00977080) study assessed whether dose-titrated… (More)
Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009.
BACKGROUND Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents (ESAs) and in CKD patients treated to haemoglobin (Hb) targets above the labeled range of 10-12… (More)
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT…
BACKGROUND Paricalcitol and cinacalcet are common therapies for patients on haemodialysis with secondary hyperparathyroidism (SHPT). We conducted a multi-centre study in 12 countries to compare the… (More)
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
BACKGROUND In this Phase 4 international study, efficacy and safety of paricalcitol-centred therapy were compared with that of cinacalcet-centred therapy for the treatment of chronic kidney disease… (More)